Harris Erik's Form 4 filing
Ultragenyx Pharmaceutical Inc. (RARE) · filed Mar 4, 2025
- Accession no.
- 0000950170-25-032773
- Filed
- Mar 4, 2025
- Trade date
- Mar 1-3, 2025
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $635.8K. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Harris ErikCIK 0001780113 | Officer (EVP & Chief Commercial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 1, 2025 | Common Stock | AGrant or awardAcquired | +16,813 | $0.00 | $0 | 83,976 | Direct | |
| Mar 1, 2025 | Common Stock | AGrant or awardAcquired | +18,443 | $0.00 | $0 | 102,419 | Direct | |
| Mar 3, 2025 | Common Stock | SSaleDisposed | −15,103 | $42.10 | −$635,836.3 | 87,855 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 1, 2025 | Common Stock | AGrant or awardAcquired | +30,246 | $0.00 | $0 | 30,246 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.